Boehringer Ingelheim Awarded Perfect Score on Human Rights Campaign Foundation's Corporate Equality Index

Nov 18, 2015, 11:30 ET from Boehringer Ingelheim Pharmaceuticals, Inc.

RIDGEFIELD, Conn., Nov. 18, 2015 /PRNewswire/ -- Boehringer Ingelheim announced today that it has been recognized on the 2016 Corporate Equality Index (CEI). This is the eighth time that the company received a perfect score and has been designated as a Best Place to Work for LGBT Equality. Administered by the Human Rights Campaign Foundation, the CEI is a national benchmarking report on corporate policies and practices related to workplace equality for lesbian, gay, bisexual and transgender employees.

"Our employees should always feel like they can bring their whole and true selves to work," said Nancy Di Dia, chief diversity and inclusion officer, Boehringer Ingelheim. "Providing a diverse and inclusive environment is a critical part of our culture. We strive for diversity of the individual, but also the diversity of ideas and experiences, which benefits our employees, and, ultimately, helps us to more effectively serve our broad patient population."

"In this 2016 Corporate Equality Index, hundreds of major businesses responded to our new standards for workplace equality with exceptional leadership," said Deena Fidas, workplace equality program director, Human Rights Campaign Foundation. "Boehringer Ingelheim not only meets these standards, it goes above and beyond the call of duty, making commitment to equality a fundamental aspect of its corporate values."

The 2016 CEI rated 1,027 businesses in the report, which evaluates LGBT-related policies and practices including non-discrimination workplace protections, domestic partner benefits, transgender-inclusive health care benefits, competency programs, and public engagement with the LGBT community. Boehringer Ingelheim's efforts in satisfying all of the CEI's criteria resulted in a 100 percent score. The company is among only 407 major U.S. businesses that earned top marks this year.

Boehringer Ingelheim's CEI perfect score is the latest accolade in a series of recent corporate award wins, including:

  • Thomson Reuters' Top 100 Global Innovators;
  • Science magazine's Top Employer list; and
  • Working Mother magazine's 100 Best Companies.

For more information on the 2016 Corporate Equality Index, or to download a free copy of the report, visit www.hrc.org/cei.

About Boehringer Ingelheim Pharmaceuticals, Inc.
Boehringer Ingelheim Pharmaceuticals, Inc., based in Ridgefield, CT, is the largest U.S. subsidiary of Boehringer Ingelheim Corporation.

Boehringer Ingelheim is one of the world's 20 leading pharmaceutical companies. Headquartered in Ingelheim, Germany, the company operates globally with 146 affiliates and more than 47,000 employees. Since its founding in 1885, the family-owned company has been committed to researching, developing, manufacturing and marketing novel treatments for human and veterinary medicine.

Boehringer Ingelheim is committed to improving lives and providing valuable services and support to patients and families. Our employees create and engage in programs that strengthen our communities. To learn more about how we make more health for more people, visit our Corporate Social Responsibility Report.

In 2014, Boehringer Ingelheim achieved net sales of about $16.96 billion dollars (13.3 billion euros). R&D expenditure corresponds to 19.9 percent of its net sales.

For more information please visit www.us.boehringer-ingelheim.com, or follow us on Twitter @BoehringerUS.  

About the Human Rights Campaign
The Human Rights Campaign is America's largest civil rights organization working to achieve lesbian, gay, bisexual and transgender equality. By inspiring and engaging all Americans, HRC strives to end discrimination against LGBT citizens and realize a nation that achieves fundamental fairness and equality for all.

Contact:
Boehringer Ingelheim Pharmaceuticals, Inc.
Name: Kate O'Connor
Phone: (203) 791-6250 
Email: kate.oconnor@boehringer-ingelheim.com

Photo - http://photos.prnewswire.com/prnh/20151117/288631
Photo - http://photos.prnewswire.com/prnh/20151117/288632  

SOURCE Boehringer Ingelheim Pharmaceuticals, Inc.